VIPoma laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Madhu Sigdel (talk | contribs) No edit summary |
Madhu Sigdel (talk | contribs) No edit summary |
||
| Line 8: | Line 8: | ||
Laboratory findings consistent with the diagnosis of VIPoma include:<ref name="pmid16357627">{{cite journal| author=Remme CA, de Groot GH, Schrijver G| title=Diagnosis and treatment of VIPoma in a female patient. | journal=Eur J Gastroenterol Hepatol | year= 2006 | volume= 18 | issue= 1 | pages= 93-9 | pmid=16357627 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16357627 }} </ref><ref name="pmid17510774">{{cite journal| author=Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ| title=Pancreatic VIPomas: subject review and one institutional experience. | journal=J Gastrointest Surg | year= 2008 | volume= 12 | issue= 2 | pages= 382-93 | pmid=17510774 | doi=10.1007/s11605-007-0177-0 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17510774 }} </ref> | Laboratory findings consistent with the diagnosis of VIPoma include:<ref name="pmid16357627">{{cite journal| author=Remme CA, de Groot GH, Schrijver G| title=Diagnosis and treatment of VIPoma in a female patient. | journal=Eur J Gastroenterol Hepatol | year= 2006 | volume= 18 | issue= 1 | pages= 93-9 | pmid=16357627 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16357627 }} </ref><ref name="pmid17510774">{{cite journal| author=Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ| title=Pancreatic VIPomas: subject review and one institutional experience. | journal=J Gastrointest Surg | year= 2008 | volume= 12 | issue= 2 | pages= 382-93 | pmid=17510774 | doi=10.1007/s11605-007-0177-0 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17510774 }} </ref> | ||
*Elevated serum vasoactive intestinal polypeptide (VIP) levels: Normal fasting serum VIP level is generally < 75pg/ml whereas VIPomas have levels generally > 500pg/ml.<ref name="pmid23582916">{{cite journal| author=Ito T, Igarashi H, Jensen RT| title=Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. | journal=Best Pract Res Clin Gastroenterol | year= 2012 | volume= 26 | issue= 6 | pages= 737-53 | pmid=23582916 | doi=10.1016/j.bpg.2012.12.003 | pmc=3627221 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23582916 }}</ref> VIP level > 200pg/ml is strongly suggestive of VIPoma. Hormone measurement taken at the time of diarrhea episode has the highest yield as VIP secretion is during period of diarrhea and has short t1/2 (approx. 2 mins in blood). Single measurement should be confirmed by repeat testing. | *Elevated serum vasoactive intestinal polypeptide (VIP) levels: Normal fasting serum VIP level is generally < 75pg/ml whereas VIPomas have levels generally > 500pg/ml.<ref name="pmid23582916">{{cite journal| author=Ito T, Igarashi H, Jensen RT| title=Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. | journal=Best Pract Res Clin Gastroenterol | year= 2012 | volume= 26 | issue= 6 | pages= 737-53 | pmid=23582916 | doi=10.1016/j.bpg.2012.12.003 | pmc=3627221 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23582916 }}</ref> VIP level > 200pg/ml is strongly suggestive of VIPoma. Hormone measurement taken at the time of diarrhea episode has the highest yield as VIP secretion is during period of diarrhea and has short t1/2 (approx. 2 mins in blood). Single measurement should be confirmed by repeat testing. | ||
*Elevated pancreatic polypeptide levels and neurotensin levels. | *Elevated pancreatic polypeptide levels (Normal < 312pg/ml) and neurotensin levels. | ||
*Low serum [[potassium]], [[bicarbonate]], and [[magnesium]] levels secondary to fecal loss. | *Low serum [[potassium]], [[bicarbonate]], and [[magnesium]] levels secondary to fecal loss. | ||
*High calcium levels secondary to fecal loss. | *High calcium levels secondary to fecal loss. | ||
Revision as of 20:23, 5 January 2018
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma laboratory findings On the Web |
|
American Roentgen Ray Society Images of VIPoma laboratory findings |
|
Risk calculators and risk factors for VIPoma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3]
Overview
Laboratory tests used in the diagnosis of VIPoma include serum vasoactive intestinal polypeptide (VIP) levels, basal gastric acid output, potassium, bicarbonate, magnesium, and calcium levels.[1][2]
Laboratory Findings
Laboratory findings consistent with the diagnosis of VIPoma include:[1][2]
- Elevated serum vasoactive intestinal polypeptide (VIP) levels: Normal fasting serum VIP level is generally < 75pg/ml whereas VIPomas have levels generally > 500pg/ml.[3] VIP level > 200pg/ml is strongly suggestive of VIPoma. Hormone measurement taken at the time of diarrhea episode has the highest yield as VIP secretion is during period of diarrhea and has short t1/2 (approx. 2 mins in blood). Single measurement should be confirmed by repeat testing.
- Elevated pancreatic polypeptide levels (Normal < 312pg/ml) and neurotensin levels.
- Low serum potassium, bicarbonate, and magnesium levels secondary to fecal loss.
- High calcium levels secondary to fecal loss.
- Low basal gastric acid output.
References
- ↑ 1.0 1.1 Remme CA, de Groot GH, Schrijver G (2006). "Diagnosis and treatment of VIPoma in a female patient". Eur J Gastroenterol Hepatol. 18 (1): 93–9. PMID 16357627.
- ↑ 2.0 2.1 Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ (2008). "Pancreatic VIPomas: subject review and one institutional experience". J Gastrointest Surg. 12 (2): 382–93. doi:10.1007/s11605-007-0177-0. PMID 17510774.
- ↑ Ito T, Igarashi H, Jensen RT (2012). "Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances". Best Pract Res Clin Gastroenterol. 26 (6): 737–53. doi:10.1016/j.bpg.2012.12.003. PMC 3627221. PMID 23582916.